Using the Xerna TME Panel, researchers analyzed pre-treatment tumor biopsies to classify patients who went on to receive durvalumab maintenance therapy or active surveillance only as immune score ...

WALTHAM, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to ...

BOSTON--(BUSINESS WIRE)--Genialis, a leader in applied data science for the development of precision medicines, today announced it will leverage its proprietary ResponderID AI platform technology to ...

QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna™ TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s ...

Genialis is the RNA biomarker company; it espouses a people-first approach to machine learning–driven biomarker discovery. For targeted therapies to benefit the most patients possible, Genialis ...

Genialis has created ResponderID, a machine-learning platform that unravels complex biological signatures from patient data to deliver next-generation biomarkers for diagnostic and drug development.

Xerna TME Panel has potential to predict patient responses to angiogenic- and immune-targeted therapies WALTHAM, Mass., April 11, 2022 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc. (“OncXerna”) is a ...

With a new partnership with India-based 4baseCare, Genialis addresses the gap in data representation to ensure its AI/ML models work in more diverse populations Over 15,000 patient samples from a ...

Better 24-month survival was achieved when durvalumab was used for maintenance compared to surveillance in esophagogastric adenocarcinoma patients with“high” Xerna TME Panel immune scores, despite ...

HILDEN, Germany & WALTHAM, Mass. & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) and OncXerna Therapeutics, Inc. (“OncXerna ...